BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34745562)

  • 1. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland.
    Nowicki M; Komar M; Kusztal M; Mizia-Stec K; Liberek T; Małyszko J; Muras-Szwedziak K; Pawlaczyk K; Podolec P; Sławek J
    F1000Res; 2021; 10():841. PubMed ID: 34745562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
    Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
    Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
    Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
    Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
    Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
    J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.
    Suntjens EB; Smid BE; Biegstraaten M; Dreschler WA; Hollak CE; Linthorst GE
    J Inherit Metab Dis; 2015 Mar; 38(2):351-8. PubMed ID: 25395255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heart in Fabry's disease.
    Sheppard MN
    Cardiovasc Pathol; 2011; 20(1):8-14. PubMed ID: 19919901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
    Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
    Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
    J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease.
    Nowak A; Koch G; Huynh-Do U; Siegenthaler M; Marti HP; Pfister M
    Kidney Blood Press Res; 2017; 42(1):1-15. PubMed ID: 28253518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
    Laffer B; Lenders M; Ehlers-Jeske E; Heidenreich K; Brand E; Köhl J
    Front Immunol; 2024; 15():1307558. PubMed ID: 38304433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD77 levels over enzyme replacement treatment in Fabry Disease Family (V269M).
    Pereira EM; Silva ASD; Silva RND; Monte Neto JT; Nascimento FFD; Sousa JLM; Costa Filho HCSAL; Sales Filho HLA; Labilloy A; Monte SJHD
    J Bras Nefrol; 2018; 40(4):333-338. PubMed ID: 29927462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision medicine in Fabry disease.
    Lenders M; Brand E
    Nephrol Dial Transplant; 2021 Jun; 36(Suppl 2):14-23. PubMed ID: 34153986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
    Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
    Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is just enzyme replacement therapy enough for Fabry disease treatment? Have we missed a trick?
    Ozer H; Baloglu I; Topkac A; Ozturk Y; Yonet F; Daglı F; Kilinc İ; Turkmen K
    Nefrologia (Engl Ed); 2024; 44(2):217-223. PubMed ID: 37179210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening.
    Chen Z; Yin B; Jiao J; Ye T
    BMC Nephrol; 2024 Feb; 25(1):61. PubMed ID: 38383316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for health-related quality of life and its determinants in Fabry disease: A cross-sectional multicenter study.
    Winter Y; Hilz M; Beuschlein F; Tsukimura T; Seifritz E; Lenders M; Brand E; Hennermann JB; Nowak A
    Mol Genet Metab; 2023 Nov; 140(3):107692. PubMed ID: 37703724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation.
    Pietilä-Effati P; Söderström J; Saarinen JT; Löyttyniemi E; Kantola I
    Mol Genet Genomic Med; 2022 May; 10(5):e1915. PubMed ID: 35246967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.